IL-6 is present in beta and alpha cells in human pancreatic islets: Expression is reduced in subjects with type 1 diabetes.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
02 2020
Historique:
received: 04 09 2019
revised: 27 11 2019
accepted: 29 11 2019
pubmed: 7 12 2019
medline: 5 8 2020
entrez: 7 12 2019
Statut: ppublish

Résumé

IL-6 is a pro-inflammatory cytokine upregulated in some autoimmune diseases. The role of IL-6 in the development of type 1 diabetes (T1D) is unclear. Clinical studies are investigating whether tocilizumab (anti-IL-6 receptor) can help preserve beta cell function in patients recently diagnosed with T1D. However, in some rodent models and isolated human islets, IL-6 has been found to have a protective role for beta cells by reducing oxidative stress. Hence, we systematically investigated local tissue expression of IL-6 in human pancreas from non-diabetic, auto-antibody positive donors and donors with T1D and T2D. IL-6 was constitutively expressed by beta and alpha cells regardless of the disease state. However, expression of IL-6 was highly reduced in insulin-deficient islets of donors with T1D, and the expression was then mostly restricted to alpha cells. Our findings suggest that the implication of IL-6 in T1D pathogenesis might be more complex than previously assumed.

Identifiants

pubmed: 31809899
pii: S1521-6616(19)30479-6
doi: 10.1016/j.clim.2019.108320
pmc: PMC6961707
mid: NIHMS1547447
pii:
doi:

Substances chimiques

IL6 protein, human 0
Interleukin-6 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108320

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI092453
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134971
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
Islets. 2013 Mar-Apr;5(2):95-105
pubmed: 23510983
Diabetes. 2018 Aug;67(8):1576-1588
pubmed: 29784660
FASEB J. 2017 Sep;31(9):4140-4152
pubmed: 28592636
Diabetes. 2012 Aug;61(8):2030-6
pubmed: 22596052
J Autoimmun. 2017 Jul;81:68-73
pubmed: 28325643
J Immunol. 1991 Jul 1;147(1):117-23
pubmed: 2051017
J Immunol. 1998 Dec 15;161(12):6480-6
pubmed: 9862671
Diabetes. 2006 Oct;55(10):2688-97
pubmed: 17003332
Nat Med. 2011 Oct 30;17(11):1481-9
pubmed: 22037645
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Sci Transl Med. 2016 Sep 14;8(356):356ra119
pubmed: 27629486
Diabetologia. 2016 Mar;59(3):492-501
pubmed: 26602422
FASEB J. 2015 May;29(5):1805-16
pubmed: 25609426
J Autoimmun. 2014 Dec;55:24-32
pubmed: 24582317
Blood. 1989 Jul;74(1):1-10
pubmed: 2473791
Diabetes. 2007 Sep;56(9):2356-70
pubmed: 17579207
Drug Des Devel Ther. 2014 Mar 28;8:349-64
pubmed: 24729685
PLoS One. 2010 Dec 13;5(12):e14328
pubmed: 21179199
J Clin Invest. 1991 Feb;87(2):739-42
pubmed: 1899431
J Immunol. 1989 Aug 15;143(4):1188-91
pubmed: 2501390
Endocrine. 2002 Mar;17(2):135-40
pubmed: 12041915
Eur J Immunol. 1988 Nov;18(11):1797-801
pubmed: 2462501
Endocrinology. 2009 Dec;150(12):5218-29
pubmed: 19819943
Biochim Biophys Acta. 2011 May;1813(5):878-88
pubmed: 21296109
Am J Pathol. 1994 Jul;145(1):157-66
pubmed: 8030746
Cell Rep. 2017 Apr 11;19(2):267-280
pubmed: 28402851
PLoS Genet. 2013 Apr;9(4):e1003444
pubmed: 23593036
J Neurol Sci. 1997 Feb 27;146(1):59-65
pubmed: 9077497
J Immunol. 2009 Oct 1;183(7):4432-9
pubmed: 19748982
J Endocrinol. 2012 Sep;214(3):301-11
pubmed: 22761278
Diabetes. 2005 Dec;54 Suppl 2:S114-24
pubmed: 16306329
J Immunol. 2010 Oct 1;185(7):3814-8
pubmed: 20810982
Annu Rev Pharmacol Toxicol. 2012;52:199-219
pubmed: 21910626
PLoS One. 2012;7(8):e42971
pubmed: 22937006
Cell Metab. 2019 Apr 2;29(4):844-855.e3
pubmed: 30595477
Diabetes. 2017 May;66(5):1334-1345
pubmed: 28137793
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13163-8
pubmed: 18719127
Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):40-3
pubmed: 18091322

Auteurs

Sakthi Rajendran (S)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Florence Anquetil (F)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Estefania Quesada-Masachs (E)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Madeleine Graef (M)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Nathaly Gonzalez (N)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Sara McArdle (S)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Tiffany Chu (T)

La Jolla Institute for Immunology, La Jolla, CA, United States of America.

Lars Krogvold (L)

Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Odontology, University of Oslo, Oslo, Norway.

Knut Dahl-Jørgensen (K)

Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.

Matthias von Herrath (M)

La Jolla Institute for Immunology, La Jolla, CA, United States of America. Electronic address: matthias@lji.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH